Healthcare Industry News:  benign prostatic hyperplasia 

Biopharmaceuticals Generics Litigation

 News Release - November 8, 2007

Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case

TOKYO and RIDGEFIELD, Conn., Nov. 8 (HSMN NewsFeed) -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax® (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).

As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.

Source: Boehringer Ingelheim

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.